Switzerland· 67205002
Kanjinti
A trastuzumab product containing trastuzumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Trastuzumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD01 (trastuzumab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Trastuzumab · ATC L01FD01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trastuzumab costs, country by country.
Normalised to the WHO defined daily dose (28.6 mg), so markets compare like for like.
- Switzerland: $116.57 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Trastuzumab · price per daily dose (28.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$116.57
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- trastuzumabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01FD01
- ATC class
- Trastuzumab
- Defined daily dose
- 28.6 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680672050027Durchstf 1 StkCHF 1469
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for trastuzumab.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trastuzumab · interactions on record
81 records
- 34 severe
- 47 moderate
Most severe, free to view
- CladribineL01BB04severe
- DoxorubicinL01DB01severe
- DaunorubicinL01DB02severe
- EpirubicinL01DB03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trastuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomHerceptin 150mg powder for concentrate for solution for infusion vialsRoche Products Ltd
- FinlandDazublysCuraTeQ Biologics (Malta) Limited
- CzechiaDAZUBLYSCuraTeQ Biologics (Malta) Limited, Floriana
- BelgiumDazublys 150 mgCuraTeQ Biologics (Malta)
- SwedenDazublys 150 mg Pulver till koncentrat till infusionsvätska, lösningCuraTeQ Biologics (Malta) Limited
- PolandDazublysCuraTeQ Biologics s.r.o.
- IcelandDazublysCuraTeQ Biologics (Malta) Limited
- IrelandDazublys 150 mg powder for concentrate for solution for infusionCurateq Biologics s.r.o.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazublys, Herceptin
- Liechtenstein · Dazublys, Herceptin
- Norway · Dazublys, Herceptin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffb40955-5229-4b67-bc7b-7d4caaa99c46 GET /v1/drugs/ffb40955-5229-4b67-bc7b-7d4caaa99c46?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "trastuzumabum 440 mg",
"valid_from": "2020-02-01",
"limitations": "[{\"description\":\"<b>KANJINTI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms</b><br>\\nEs gelten die entsprechenden Vergütungskriterien gemäss der Limitation für Pertuzumab (siehe Limitation PERJETA) und bezüglich der Rückerstattung für KANJINTI in dieser Kombination gilt <b>zusätzlich</b> folgende Limitation:<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede adjuvant (postoperativ) bezogene Packung KANJINTI in Kombination mit Pertuzumab (PERJETA) einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21018.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21018.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-06-01\",\"validTo\":\"2028-06-30\"},{\"description\":\"<b>Weitere Indikationen</b><br>\\nFür die zugelassenen Indikationen und für andere Kombinationen, sofern entsprechend Limitierung der Kombinationspartner eine Vergütung vorgesehen, gelten die in der SL aufgeführten Preise (ohne Preismodell) von KANJINTI.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21018.02\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2022-02-01\",\"validTo\":null}]",
"galenic_form": "Trockensub 440 mg c Solv",
"therapeutic_area": null,
"sl_inclusion_date": "2020-02-01",
"self_retention_pct": 10
}See everything about trastuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.